Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | CFTR | P13569 | 2/20 | 0.33 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748180 | 0.89 | KCNA5 (0.33) | KCNA5KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23748259 | 0.83 | SMN1; SMN2 (0.44) | KCNA5KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23748287 | 0.83 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23748138 | 0.75 | SMN1; SMN2 (0.44) | KCNA5KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24834939 | 0.74 | MAPT (0.37) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL23748170 | 0.73 | KDM4E (0.32) | SLC6A2SLC6A4SLC6A3OPRD1CYP2C19 | |
| SCHEMBL23748324 | 0.69 | CYP3A4 (0.36) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL23748227 | 0.68 | SLC6A2 (0.33) | KCNA5KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15475920 | 0.67 | PARP1 (0.35) | — | |
| SCHEMBL23748253 | 0.67 | MEN1 (0.39) | SLC6A2SLC6A4SLC6A3CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | Janssen Biopharma, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3864020-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | Janssen BioPharma, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195502-A | Macrocyclic influenza endonuclease inhibitors | 詹森生物制药有限公司 | 2021-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | ACE, FEN1, PNP | KCNA5 2587/4885KCNH2 3048/4885SLC6A2 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.